Year All20262025202420232022202120202019201820172016201520142013 March 18, 2026 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read more March 11, 2026 Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Read more February 24, 2026 Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read more February 23, 2026 Arvinas to Participate in Upcoming Investor Conferences Read more February 17, 2026 Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Read more February 12, 2026 Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director Read more
March 18, 2026 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read more
March 11, 2026 Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Read more
February 24, 2026 Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read more
February 17, 2026 Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Read more
February 12, 2026 Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director Read more
